Helicobacter pylori Infections
Also known as: H. pylori infections
Methodology & AI Transparency ⓘ
Helicobacter pylori Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Helicobacter pylori (H.
- 2 Real-world patient consensus: Diagnostic registry K21.1: Helicobacter pylori Infections is managed within GERD & Stomach (aka H. pylori infections).
- 3 Typical cash cost range: Clinicians assessing Helicobacter pylori Infections focus on visceral hypersensitivity [Helicobacter pylori Infections K21.1] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Helicobacter pylori Infections monitoring tracks Serum Vitamin B12 in Helicobacter pylori Infections (K21.1: & Magnesium (chronic) toward B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K21.1).
Ask our AI Specialists anything about Helicobacter pylori Infections
What Is Helicobacter pylori Infections?
Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers , and it can also cause gastritis and stomach cancer . About 30 to 40% of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids.
Pathophysiology, Underlying Causes & Clinical Presentation
In Helicobacter pylori Infections (K21.1), physiological disruption stems from visceral hypersensitivity [Helicobacter pylori Infections K21.1], Cross-referenced with NIH MeSH (Helicobacter Infections), informing Acid Reflux, GERD & Upper GI Health protocols that track H. pylori Stool in Helicobacter pylori Infections (K21.1: Antigen or Urea) (Negative (K21.1)).
Common Symptoms & Clinical Signs
- • Wash your hands after using the bathroom and before eating
- • Eat properly prepared food
- • Presentation of Helicobacter pylori Infections (K21.1): epigastric burning, early in Helicobacter pylori Infections (K21.1: satiety, or upper-abdominal)
- • Secondary Helicobacter pylori Infections clinical sign: chronic throat clearing, in Helicobacter pylori Infections (K21.1: hoarseness, nocturnal cough,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Helicobacter pylori Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K21.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Helicobacter pylori Infections (K21.1: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K21.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Helicobacter pylori Infections (K21.1: Antigen or Urea) | Negative (K21.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Helicobacter pylori Infections (K21.1: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (K21.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Helicobacter pylori Infections
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Pylera • RxCUI 1294619 | Nitroimidazole Antimicrobial | 81% | $2.4278 | $ 106.82 /mo |
| Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Hpyl Homo • RxCUI RXN-B437422117 | Over-the-Counter Clinical Monograph | 87% | $1.3800 | $ 107.86 /mo |
| Idkit Hp One (Citric Acid Anhydrous and 13c Urea) Idkit Hp One • RxCUI RXN-B50402100 | Helicobacter pylori Diagnostic | 91% | $1.8700 | $ 143.14 /mo |
| Vonoprazan Fumarate and Amoxicillin Voquezna Dual Pak • RxCUI 308191 | FDA Prescription Therapeutic Agent | 91% | $7.4822 | $ 185.00 /mo |
| Citric Acid Anhydrous and 13c Urea Idkit Hp One • RxCUI RXN-50402100-1736 | Helicobacter pylori Diagnostic | 76% | $2.0600 | $ 91.93 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Helicobacter pylori Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the: What a 1,046-Participant Study Found Both vonoprazan-based regimens were superior to proton pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population. Gastroenterology • 2022-09-15 • Phase III Randomized Trial | N = 1,046 | 96/100 | PMID 35679950 ↗ |
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| New Insights on Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and: What a 263-Participant Study Found Vonoprazan was well tolerated and non-inferior to lansoprazole for duodenal ulcer healing and achieved H. Journal of gastroenterology and hepatology • 2022-07-15 • Phase III Randomized Trial | N = 263 | 93/100 | PMID 35342997 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of keverprazan-based quadruple therapy for Helicobacter pylori Keverprazan 20 mg twice daily, used as a component of bismuth quadruple therapy, provided effective H. International journal of antimicrobial agents • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39293772 ↗ |
| Can This Approach Help? Inside the Latest Research on Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Over 50% of initial nonresponders achieved clinical response with extended risankizumab treatment. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-05-15 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 40953785 ↗ |
Helicobacter pylori Infections Patient Community & “People Like Me” Threads
Filter Helicobacter pylori Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.